SZLSF (StageZero Life Sciences) Other Stockholders Equity: $-0.00 Mil (As of Sep. 2024)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.01
View Full Analysis

What is StageZero Life Sciences Other Stockholders Equity?

StageZero Life Sciences SZLSF 10 Other Stockholders Equity is $-0.00 Mil as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $-0.00 Mil.

StageZero Life Sciences's quarterly Other Stockholders Equity declined from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($-0.00 Mil).

StageZero Life Sciences's annual Other Stockholders Equity increased from Dec. 2020 ($-0.00 Mil) to Dec. 2021 ($0.00 Mil) but then declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil).

StageZero Life Sciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Other Stockholders Equity Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00
SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
StageZero Life Sciences (SZLSF) has a Other Stockholders Equity of $-0.00 Mil as of Sep. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Other Stockholders Equity too high?
StageZero Life Sciences' current Other Stockholders Equity is $-0.00 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Other Stockholders Equity compare to IDTA and TTOO?
StageZero Life Sciences' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Other Stockholders Equity is $-0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price